Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia
Abstract
Abstract We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants who showed improvements in multilineage blood cell counts, even with daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT05832216.
Article Details
Authors (19)
Zhen Gao
State Key Laboratory of Optical Fiber and Cable Manufacturing Technology, Department of Electronic and Electrical Engineering, Guangdong Key Laboratory of Integrated Optoelectronics Intellisense, Southern University of Science and Technology
Hong Pan
Lele Zhang
Weiwang Li
Blood Diseases Hospital, Tianjin, China
Ruonan Li
State Key Laboratory of Experimental Hematology, Tianjin, China
Jingyu Zhao
Blood Diseases Hospital, Tianjin, China
Yuechen Luo
State Key Laboratory of Experimental Hematology, Tianjin, China
Yu Lian
4Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China
Xiao Yu
Zhexiang Kuang
Blood Diseases Hospital, Tianjin, China
Neng Nie
Blood Diseases Hospital, Tianjin, China
Jianping Li
Jinbo Huang
Blood Diseases Hospital, Tianjin, China
Xin Zhao
Yuan Li
Liwei Fang
Blood Diseases Hospital, Tianjin, China
Meili Ge
Blood Diseases Hospital, Tianjin, China
Yizhou Zheng
Blood Diseases Hospital, Tianjin, China
Jun Shi